Claroid Pharmaceuticals Limited

• Funding of capital expenditure requirement for setting up of the Proposed Plant₹168 Cr
• General Corporate Purposes

Except as stated in this section, as on the date of this Draft Red herring Prospectus, there are no outstanding (i) criminal proceedings (including matters which are at FIR stage even if no cognizance has been taken by any court); (ii) all actions (including all disciplinary actions, penalties and show cause notices) taken by statutory or regulatory authorities; (iii) claims related to direct and indirect taxes in a consolidated manner; and (iv) other pending material litigations (including civil litigation or arbitration proceeding, in each case involving our Company, Directors, Promoters (collectively, the “Relevant Parties”) and (v) litigation involving our Group Companies which have a material impact on our Company. Further, there are no disciplinary actions (including penalties) imposed by SEBI or stock exchanges against our Promoters or Directors in the last five Fiscals immediately preceding the date of this Draft Red Herring Prospectus, including any outstanding action. Furthermore, except as disclosed in this section, there are no outstanding (i) criminal proceedings; and (ii) actions by regulatory and/ or statutory authorities involving our Key Managerial Personnel and Senior Management.

• The Company derives a substantial portion of its revenue from exports to Nigeria, constituting 76.21%, 66.93% and 95.30% of revenue from operations for Fiscal 2026, 2025 and 2024 respectively. Any adverse developments in Nigeria, including changes in export or trade policies, deterioration in diplomatic or international relations, political or economic instability, war, civil unrest or other disruptions, could adversely affect the business, results of operations, financial condition and cash flows.(Geographic Concentration)

• The Company's business largely depends on its top ten customers, which contributed to 62.80%, 69.83% and 81.38% of overall sale of products for Fiscal 2026, 2025 and 2024 respectively. Loss of any of these customers or revenue from them could have a material adverse effect on the business, financial condition, results of operations and cash flows. The Company typically does not enter into contracts with its distributors and conducts operations on a purchase order basis, exposing it to a significant risk of customer attrition and challenges in production planning.(Customer Concentration)

• The Company generates a significant portion of its revenues from the manufacturing of Tablets, constituting 52.06%, 48.40% and 57.90% of total sale of products for Fiscal 2026, 2025 and 2024 respectively. Factors that could negatively affect the sale of products in this segment include regulatory changes, increased market competition, supply chain disruptions, and the impact of generic competition.(Product Concentration)

• The Company's business largely depends on its top ten customers, which contributed to 62.80%, 69.83% and 81.38% of overall sale of products for Fiscal 2026, 2025 and 2024 respectively. The loss of one or more key distributors, or a significant reduction in orders from them, for any reason, including an inability to negotiate acceptable terms, failure to renew business arrangements, disputes, customer financial distress or insolvency, mergers or acquisitions involving distributors, changes in distributor requirements, or work stoppages, could materially and adversely affect revenue and profitability.(Customer Concentration)

• The Company's business largely depends on its top ten customers, which contributed to 62.80%, 69.83% and 81.38% of overall sale of products for Fiscal 2026, 2025 and 2024 respectively. Adverse developments involving any of the key distributors, including reduction or discontinuation of orders, disputes, or disqualifications, could have a material impact on revenues, cash flows, and liquidity. Key distributors may choose to reduce dependence on the Company, switch to competitors, adopt alternative products, or not continue to place orders on favourable terms.(Customer Concentration)

• The Company's business largely depends on its top ten customers, which contributed to 62.80%, 69.83% and 81.38% of overall sale of products for Fiscal 2026, 2025 and 2024 respectively. The Company cannot assure that it will be able to retain such distributors or reduce its dependence on a limited number of them. Any such development could materially and adversely affect the business, results of operations, financial condition and cash flows.(Customer Concentration)

• The Company's business largely depends on its top ten customers, which contributed to 62.80%, 69.83% and 81.38% of overall sale of products for Fiscal 2026, 2025 and 2024 respectively. The Company cannot assure that the same will not happen in the future regarding the loss of key distributors, as it has not suffered any loss in the last three Fiscals.(Customer Concentration)

• The Company generates a significant portion of its revenues from the manufacturing of Tablets, constituting 52.06%, 48.40% and 57.90% of total sale of products for Fiscal 2026, 2025 and 2024 respectively. This segment encompasses a wide range of products, including anti-infectives, anti-malarials, anti-inflammatory and analgesic products, cardiovascular and anti-hypertensive products, anti-diabetic products, anthelmintics and enzyme preparations.(Product Concentration)

Each bar is a fixed formula applied to the figures shown above, scored 0–100. This is a reading of what the company disclosed — not a recommendation to apply or avoid, not a price target, and not a prediction of listing performance. Dimensions that could not be extracted are excluded rather than assumed, so coverage varies between documents.